PROK
ProKidney Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.25
P/S
615.99
EV/EBITDA
-3.00
DCF Value
$0.88
FCF Yield
-24.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-218.8%
Operating Margin
-18477.8%
Net Margin
-7725.2%
ROE
6.9%
ROA
-20.6%
ROIC
-54.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $225.0K | $-19.2M | $-0.14 |
| FY 2025 | $893.0K | $-69.0M | $-0.52 |
| Q3 2025 | $217.0K | $-16.5M | $-0.12 |
| Q2 2025 | $221.0K | $-16.6M | $-0.13 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.86
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.